Allspring Global Investments Holdings LLC Sells 40,815 Shares of LivaNova PLC (NASDAQ:LIVN)

Allspring Global Investments Holdings LLC decreased its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 4.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 788,761 shares of the company’s stock after selling 40,815 shares during the period. Allspring Global Investments Holdings LLC owned approximately 1.46% of LivaNova worth $44,123,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Headlands Technologies LLC boosted its position in LivaNova by 33.3% during the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company’s stock valued at $93,000 after acquiring an additional 451 shares in the last quarter. Teza Capital Management LLC purchased a new stake in LivaNova in the third quarter worth $275,000. Aigen Investment Management LP bought a new position in LivaNova in the fourth quarter worth $286,000. Vanguard Personalized Indexing Management LLC lifted its position in LivaNova by 34.6% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 5,521 shares of the company’s stock valued at $286,000 after buying an additional 1,418 shares during the period. Finally, Pacer Advisors Inc. boosted its holdings in shares of LivaNova by 80.8% during the 4th quarter. Pacer Advisors Inc. now owns 8,102 shares of the company’s stock valued at $419,000 after buying an additional 3,621 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $52.79 on Thursday. The firm has a market cap of $2.86 billion, a P/E ratio of -87.98 and a beta of 0.99. LivaNova PLC has a twelve month low of $42.75 and a twelve month high of $64.47. The company has a quick ratio of 2.71, a current ratio of 3.17 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $57.83 and a 200 day moving average of $54.24.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.28. The firm had revenue of $294.90 million during the quarter, compared to analysts’ expectations of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The company’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. As a group, research analysts expect that LivaNova PLC will post 2.6 EPS for the current fiscal year.

Insider Buying and Selling at LivaNova

In other news, Director Daniel Jeffrey Moore sold 56,623 shares of LivaNova stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $60.11, for a total value of $3,403,608.53. Following the completion of the sale, the director now directly owns 27,534 shares in the company, valued at $1,655,068.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Mizuho lifted their price target on shares of LivaNova from $75.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Robert W. Baird boosted their price target on LivaNova from $58.00 to $66.00 and gave the stock a “neutral” rating in a research report on Thursday, May 2nd. StockNews.com raised LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, April 25th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $72.00 price objective on shares of LivaNova in a research note on Thursday, June 6th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $66.20.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.